To view our videos, you need to
enable JavaScript. Learn how.
install Adobe Flash 9 or above. Install now.

Then come back here and refresh the page.

Ever since Viagra hit the market, drug makers have been racing to create the same experience for women that the little, blue pill has been able to do for men. This week, a Food and Drug Administration advisory panel will consider Flibanserin, a new pill from German pharmaceutical company Boehringer Ingelheim.

It is not the first time the FDA's considered a drug meant to increase a woman's sex drive, but it is the first time one is being considered that does it by changing a woman's brain chemistry.

"What the drug does is it increases dopamine and it decreases serotonin," says Dr. Kenneth Rosenberg of NewYork-Presbyterian/Weill Cornell Medical Center. "Sexuality is very complicated. There are many aspects to it, but one of the things that improves sexuality is less serotonin and more dopamine."

Rosenberg says it is not a home run by any means, because available company data shows the drug only added about one extra satisfying sexual experience a month among more than 5,000 between ages 18 to 50 testing out the drug.

Yet many psychiatrists side with Rosenberg by saying the pill is a step towards treating what they claim is a real problem that has come to be labeled as "hypoactive sexual desire disorder."

So far, no drug company has been successful in getting the FDA to approve a feminine libido booster. Many clinicians also dispute whether such a disorder really exists.

"There is no normal level of sexual desire. What's normal for you may not be normal for me, certainly wasn't normal for my mother. This is a very varying thing," says Dr. Leonore Tiefer, a professor of psychiatry for the New York University School of Medicine. "Women who have medical reasons for abrupt changes in their sexual function have other medical resources. They don't need a new diagnosis and they don't need a new brain drug."

The real concern is whether the drug industry is taking advantage of women's sexual anxieties and potentially risking safety for profit. A new documentary, "Orgasm Inc.," explores that very question. In the film, one woman agrees to be the guinea pig to test having a metal rod inserted into her spine in hopes of stimulation. The risk goes as high as paralysis, and in the end the method does not even work.

"We live in a very strange society when it comes to sex," says "Orgasms Inc." director Liz Canner. "Some of the basic sort of knowledge, that 70 percent of women need direct clitoral stimulation in order to have an orgasm, is not something that a lot of women know. We don't teach where the clitoris is, which is such an important element in sexual response."

Canner says maybe what is needed is not a pill, but a real lesson in sex education.